Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Present at Stifel 2018 Healthcare Conference

EMERYVILLE, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
November 01, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8

EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
October 01, 2018 17:07 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
September 25, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
September 04, 2018 16:38 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
September 04, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome

67% of Patients Achieved At Least a 50% Reduction in Convulsive Seizures Global Phase 3 Randomized, Controlled Study in LGS Currently Enrolling Patients EMERYVILLE, Calif., Sept. 04, 2018 (GLOBE...
August 30, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology

EMERYVILLE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
August 07, 2018 18:21 ET | Source: Zogenix, Inc.

Zogenix Prices Public Offering of Common Stock

EMERYVILLE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
August 06, 2018 17:14 ET | Source: Zogenix, Inc.

Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock

EMERYVILLE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
August 06, 2018 16:26 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Second Quarter Financial Results

Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right